Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
BARER SOL J reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Sol J. Barer received a grant of restricted share units. On May 28, 2026, Barer was awarded 10,863 restricted share units, each representing a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The units vest on May 28, 2027, and are reported as a direct holding. Following this grant, Barer holds 10,863 restricted share units linked to the company’s ordinary shares, which may also be represented by American Depositary Shares on a one-for-one basis.
BARER SOL J reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Sol J. Barer received a grant of restricted share units. On May 28, 2026, Barer was awarded 10,863 restricted share units, each representing a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The units vest on May 28, 2027, and are reported as a direct holding. Following this grant, Barer holds 10,863 restricted share units linked to the company’s ordinary shares, which may also be represented by American Depositary Shares on a one-for-one basis.
MIGNONE ROBERTO reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Roberto Mignone received a grant of 7,242 restricted share units on May 28, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The restricted share units vest on May 28, 2027, and are reported as directly owned. Following this award, Mignone’s reported holding of restricted share units is 7,242. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
MIGNONE ROBERTO reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Roberto Mignone received a grant of 7,242 restricted share units on May 28, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The restricted share units vest on May 28, 2027, and are reported as directly owned. Following this award, Mignone’s reported holding of restricted share units is 7,242. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries Limited reported results of its annual shareholder meeting held on May 28, 2026. Shareholders elected Dr. Sol J. Barer to the Board to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva’s named executive officers, with 795,976,042 votes for and 77,082,847 against. In addition, they approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm through the 2027 annual meeting.
Teva Pharmaceutical Industries Limited reported results of its annual shareholder meeting held on May 28, 2026. Shareholders elected Dr. Sol J. Barer to the Board to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva’s named executive officers, with 795,976,042 votes for and 77,082,847 against. In addition, they approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm through the 2027 annual meeting.
TEVA PHARMACEUTICAL INDUSTRIES LTD EVP, Business Development Evan Lippman reported an exercise-and-sell transaction in company stock. On May 14, 2026, he exercised restricted share units to acquire 85,849 Ordinary Shares at a conversion price of $0.00 per share.
On the same date, he sold a total of 41,658 Ordinary Shares at a weighted average price of $35.5842 per share, with individual sale prices ranging from $35.38 to $35.685. A footnote states that a portion of the sold shares was required to cover tax withholding obligations related to the RSU vesting, and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
TEVA PHARMACEUTICAL INDUSTRIES LTD EVP, Business Development Evan Lippman reported an exercise-and-sell transaction in company stock. On May 14, 2026, he exercised restricted share units to acquire 85,849 Ordinary Shares at a conversion price of $0.00 per share.
On the same date, he sold a total of 41,658 Ordinary Shares at a weighted average price of $35.5842 per share, with individual sale prices ranging from $35.38 to $35.685. A footnote states that a portion of the sold shares was required to cover tax withholding obligations related to the RSU vesting, and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
TEVA PHARMACEUTICAL INDUSTRIES LTD Executive Vice President and Chief Financial Officer Eliyahu Sharon Kalif reported an open-market sale of 153,251 Ordinary Shares on May 14, 2026 at a weighted average price of $35.6107 per share. The shares were sold in multiple trades between $35.59 and $35.80. After the sale, he directly holds 172,184 Ordinary Shares, indicating he retains a substantial equity stake. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, meaning the trade was scheduled in advance rather than timed discretionarily.
TEVA PHARMACEUTICAL INDUSTRIES LTD Executive Vice President and Chief Financial Officer Eliyahu Sharon Kalif reported an open-market sale of 153,251 Ordinary Shares on May 14, 2026 at a weighted average price of $35.6107 per share. The shares were sold in multiple trades between $35.59 and $35.80. After the sale, he directly holds 172,184 Ordinary Shares, indicating he retains a substantial equity stake. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, meaning the trade was scheduled in advance rather than timed discretionarily.
TEVA: A Form 144 filing lists ordinary shares to be sold through Citigroup Global Markets on 05/14/2026. The filing references a Restricted Share Unit Award Vesting dated 05/14/2025 and shows numeric entries including 41,658, 85,849, and 1,482,366.60.
TEVA: A Form 144 filing lists ordinary shares to be sold through Citigroup Global Markets on 05/14/2026. The filing references a Restricted Share Unit Award Vesting dated 05/14/2025 and shows numeric entries including 41,658, 85,849, and 1,482,366.60.
Teva Pharmaceutical Industries submitted notices under Form 144 reporting proposed sales of ordinary shares by affiliated holders. The filings list multiple planned dispositions dated 03/03/2026 and 03/04/2026, and record a prior sale of 345,810 shares on 02/26/2026.
Teva Pharmaceutical Industries submitted notices under Form 144 reporting proposed sales of ordinary shares by affiliated holders. The filings list multiple planned dispositions dated 03/03/2026 and 03/04/2026, and record a prior sale of 345,810 shares on 02/26/2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD Chief Accounting Officer Amir Weiss reported an open-market sale of 10,679 Ordinary Shares on May 6, 2026 at $36.00 per share. After this transaction, he directly holds 20,016 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
TEVA PHARMACEUTICAL INDUSTRIES LTD Chief Accounting Officer Amir Weiss reported an open-market sale of 10,679 Ordinary Shares on May 6, 2026 at $36.00 per share. After this transaction, he directly holds 20,016 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries EVP Europe Commercial Richard Daniell reported an open-market sale of Teva ordinary shares. On May 5, 2026, he sold 30,000 ordinary shares at $35.40 per share. After this transaction, he directly held 55,755 ordinary shares.
The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently corresponding to one ordinary share.
Teva Pharmaceutical Industries EVP Europe Commercial Richard Daniell reported an open-market sale of Teva ordinary shares. On May 5, 2026, he sold 30,000 ordinary shares at $35.40 per share. After this transaction, he directly held 55,755 ordinary shares.
The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED filed a Form 144 notice for the proposed sale of 30,000 ordinary shares through Citigroup Global Markets Inc. with an indicated aggregate amount of $1,062,000.00 and listing on NYSE.
The filing lists prior sales by Daniell Richard in early March 2026: 128,985 shares for $4,173,941.70 on 03/03/2026, 91,345 shares for $2,983,515.95 on 03/04/2026, and 17,295 shares for $547,704.98 on 03/05/2026. Shares outstanding are shown as 1,164,426,972 as of 05/05/2026.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED filed a Form 144 notice for the proposed sale of 30,000 ordinary shares through Citigroup Global Markets Inc. with an indicated aggregate amount of $1,062,000.00 and listing on NYSE.
The filing lists prior sales by Daniell Richard in early March 2026: 128,985 shares for $4,173,941.70 on 03/03/2026, 91,345 shares for $2,983,515.95 on 03/04/2026, and 17,295 shares for $547,704.98 on 03/05/2026. Shares outstanding are shown as 1,164,426,972 as of 05/05/2026.